1,2,3-Triazole-totarol conjugates as potent PIP5K1 α lipid kinase inhibitors

Bioorg Med Chem. 2024 Apr 23;105:117727. doi: 10.1016/j.bmc.2024.117727. Online ahead of print.ABSTRACTThe human phosphatidylinositol 4-phosphate 5-kinase type I α (hPIP5K1α) plays a key role in the development of prostate cancer. In this work, seventeen derivatives of the natural diterpene totarol were prepared by copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition reaction of the correspondingO-propargylated totarol with aryl or alkyl azides and screened for their inhibitory activities toward hPIP5K1α. Five compounds, 3a, 3e, 3f, 3i, and 3r, strongly inhibited the enzyme activity with IC50 values of 1.44, 0.46, 1.02, 0.79, and 3.65 µM, respectively, with the most potent inhibitor 3e 13-[(1-(3-nitrophenyl)triazol-4yl)methoxy]-totara-8,11,13-triene). These compounds were evaluated on their antiproliferative effects in a panel of prostate cancer cell lines. Compound 3r inhibited the proliferation of LNCaP, PC3 and DU145 cells at 20 µM, strongly, but also has strong cytotoxic effects on all tested cells.PMID:38669736 | DOI:10.1016/j.bmc.2024.117727
Source: Bioorganic and Medicinal Chemistry - Category: Chemistry Authors: Source Type: research